Side-by-side financials for ERNA and JNJ. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ERNA | JNJ |
|---|---|---|
| Market cap | - | $574.10 B |
| US-listed rank | - | #20 |
| Revenue (latest FY) | $582.00K | $94.19B |
| Net income (latest FY) | -$14.08M | $26.80B |
| Net margin | -2419.9% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,000 | 984 |
In their latest fiscal years, Eterna Therapeutics Inc. reported $582.00K in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Eterna Therapeutics Inc. and JOHNSON & JOHNSON, or browse the full rankings.